AmpliPhi BioSciences has lined up $13 million in private placement cash, selling stock and warrants to fund its pipeline of treatments for drug-resistant bacterial infections.
Avita Medical Ltd (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a placement to sophisticated and institutional investors and launched a Share Purchase Plan (“SPP”).
Read more about Avita Announces $A5M Placement and Initiates Share Purchase Plan
AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, including both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE: XON), to raise approximately $13,000,000 in a private placement financing.
Read more about AmpliPhi BioSciences Corporation Announces $13 Million Financing